Abstract

Vascular dementia (VaD) is the second most common form of dementia worldwide. It is caused by cerebrovascular disease, and patients often show severe impairments of advanced cognitive abilities. Nitric oxide synthase (NOS) and nitric oxide (NO) play vital roles in the pathogenesis of VaD. The functions of NO are determined by its concentration and bioavailability, which are regulated by NOS activity. The activities of different NOS subtypes in the brain are partitioned. Pathologically, endothelial NOS is inactivated, which causes insufficient NO production and aggravates oxidative stress before inducing cerebrovascular endothelial dysfunction, while neuronal NOS is overactive and can produce excessive NO to cause neurotoxicity. Meanwhile, inflammation stimulates the massive expression of inducible NOS, which also produces excessive NO and then induces neuroinflammation. The vicious circle of these kinds of damage having impacts on each other finally leads to VaD. This review summarizes the roles of the NOS/NO pathway in the pathology of VaD and also proposes some potential therapeutic methods that target this pathway in the hope of inspiring novel ideas for VaD therapeutic approaches.

Highlights

  • This review focuses on the roles of the Nitric oxide synthase (NOS)/nitric oxide (NO) pathway in the pathogenesis of Vascular dementia (VaD), and it summarizes some of the therapies targeting this pathway for VaD treatment

  • 5.2.1. neuronal NOS (nNOS) and Neurovascular Coupling nNOS has been confirmed by many studies to have great significance in multitudinous neural signal events. nNOS-derived NO plays an essential role in learning, memory, neurogenesis, and synaptic plasticity [104,138]

  • Many therapies that are used to treat endothelial dysfunction, such as simvastatin [152] and repetitive transcranial magnetic stimulation [153], can increase the level of brain-derived neurotrophic factor (BDNF) in Alzheimer’s disease (AD) or VaD patients’ brains and improve their cognitive abilities. These results indicated that the reduction of BDNF synthesis, which is caused by the damage of the endothelial NOS (eNOS)/NO pathway, play an important role in the pathology of VaD

Read more

Summary

Introduction

Atherosclerosis, diabetes, obesity, and hypertension are common risk factors for VaD [24,25,26] These diseases keep the body in a state of chronic inflammation, thereby deteriorating the function of subcortical blood vessels, causing neuroinflammation, which causes WM damage (e.g., demyelination and axon loss), and eventually, dementia [13,22,27]. The neurovascular protective effects of the NOS/NO pathway have been founded in healthy individuals, so clarifying the way they alternate in VaD can greatly help us understand its pathological mechanisms This could provide plenty of new ideas for the development of new drugs or treatments, as well as identify more potential biomarkers to diagnose or observe the disease progression. This review focuses on the roles of the NOS/NO pathway in the pathogenesis of VaD, and it summarizes some of the therapies targeting this pathway for VaD treatment

The Pathogenesis of VaD
VaD and Inflammation
Changes in Phosphorylation of eNOS
Nervous Impairment
Substrates and Cofactors Required for NO Synthesis
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call